扩大淋巴结清扫范围对临床淋巴结阳性膀胱癌生存结局的影响
这项回顾性多中心研究纳入969例1991至2022年间接受根治性膀胱切除术的cTanyN1-3M0膀胱癌患者,比较扩大盆腔淋巴结清扫与标准盆腔淋巴结清扫的肿瘤学影响。倾向评分1:1匹配后510例分析显示,扩大清扫未改善无复发生存(HR 0.91,95%CI 0.70-1.19;P=0.5)或总生存(HR 0.78,95%CI 0.60-1.01;P=0.06),复发模式亦无差异。
要点
- 扩大盆腔淋巴结清扫较标准清扫未改善无复发生存(HR 0.91,95%CI 0.70-1.19;P=0.5)。
- 扩大清扫较标准清扫总生存HR 0.78(95%CI 0.60-1.01;P=0.06),未达统计学显著。
- 按诱导化疗分层后结局不变,复发模式在两组间无差异(P>0.05)。
核心结论
- 在临床淋巴结阳性膀胱癌患者中,根治性膀胱切除术时行扩大盆腔淋巴结清扫较标准盆腔淋巴结清扫未改善无复发生存或总生存,无论诱导化疗状态如何。
研究设计与样本
- 回顾性多中心研究,纳入969例1991至2022年间因cTany N1-3 M0膀胱癌接受根治性膀胱切除术并标准或扩大盆腔淋巴结清扫、伴或不伴铂类围手术期化疗的患者。
- 采用倾向评分1:1匹配,最终510例匹配患者纳入分析。
主要发现
- 匹配后扩大清扫组104例、标准清扫组107例出现疾病复发;136例(27%)为远处复发,47例(9.2%)为局部区域复发,19例(3.7%)为远处及局部区域复发。
- 按淋巴结清扫范围分层,复发模式无差异(P>0.05)。
- 扩大清扫较标准清扫未改善无复发生存(HR 0.91,95%CI 0.70-1.19;P=0.5)。
- 扩大清扫较标准清扫总生存HR 0.78(95%CI 0.60-1.01;P=0.06),未达统计学显著。
- 按诱导化疗分层后结局不变。
临床怎么用
- 作者认为,治疗前风险分层对于识别适合以扩大盆腔淋巴结清扫作为多模式治疗一部分行根治性膀胱切除术的理想候选者至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the oncological impact of extended pelvic lymph node dissection (ePLND) vs standard PLND (sPLND) during radical cystectomy (RC) in clinically lymph node-positive (cN+) bladder cancer (BCa). PATIENTS AND METHODS: In this retrospective, multicentre study we included 969 patients who underwent RC with sPLND (internal/external iliac and obturator lymph nodes) or ePLND (sPLND plus common iliac and presacral nodes) with or without platin-based peri-operative chemotherapy for cTany N1-3 M0 BCa between 1991 and 2022. We assessed the impact of ePLND on recurrence-free survival (RFS) and the distribution of recurrences (locoregional and distant recurrences). The secondary endpoint was overall survival (OS). We performed propensity-score matching using covariates associated with the extent of PLND in univariable logistic regression analysis. The association of the extent of PLND with RFS and OS was investigated using Cox regression models. RESULTS: Of 969 cN+ patients, 510 were 1:1 matched on propensity scores. The median (interquartile range [IQR]) time to recurrence was 8 (4-16) months, and median (IQR) follow-up of alive patients was 30 (13-51) months. Disease recurrence was observed in 104 patients in the ePLND and 107 in the sPLND group. Of these, 136 (27%), 47 (9.2%) and 19 patients (3.7%) experienced distant, locoregional, or both distant and locoregional disease recurrence, respectively. When stratified by the extent of PLND, we did not find a difference in recurrence patterns (P > 0.05). ePLND improved neither RFS (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.70-1.19; P = 0.5) nor OS (HR 0.78, 95% CI 0.60-1.01; P = 0.06) compared to sPLND. Stratification by induction chemotherapy did not change outcomes. CONCLUSION: Performing an ePLND at the time of RC in cN+ patients improved neither RFS nor OS compared to sPLND, regardless of induction chemotherapy status. Pretreatment risk stratification is paramount to identify ideal candidates for RC with ePLND as part of a multimodal treatment approach.
引用
- von Deimling M, Furrer M, Mertens LS, et al. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. BJU Int. 2023. PMID: 37904652. doi:10.1111/bju.16210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。